Clincosm LogoSign in Get a demo

Gene Polymorphism in Tinea Versicolor

Sponsor
Kasr El Aini Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04769804
Collaborator
(none)
200
Enrollment
1
Location
24
Anticipated Duration (Months)
8.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Blood samples will be taken from cases presenting with recurrent tinea versicolor , after confirmation of diagnosis by wood's light and KOH examination, for the detection of gene polymorphism in IL17 A and IL17 F.

In addition , serum samples from patients and controls will be tested for 25(OH)2 D3

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    200 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Detection of IL1-7A and IL-17F Gene Polymorphism in Pityriasis Versicolor and Its Relation to Susceptibility to Infections.
    Actual Study Start Date :
    Nov 1, 2019
    Anticipated Primary Completion Date :
    Jun 1, 2021
    Anticipated Study Completion Date :
    Nov 1, 2021

    Arms and Interventions

    Arm Intervention/Treatment
    Patients with recurrent pityriasis versicolor
    Healthy age and sex-matched controls

    Outcome Measures

    Primary Outcome Measures

    1. IL 17A gene polymorphism [6months-1 year]

      IL 17A

    2. IL 17 F gene polymorphism [6months-1 year]

      IL 17 F

    Secondary Outcome Measures

    1. Vitamin D [6months-1 year]

      Serum 25(OH)2 D3

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 60 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
      • Patients with recurrent pityriasis versicolor (active now) and not taking treatment for it.

    • Patients of both genders.

    • Age ≥18 years old.

    Exclusion Criteria:
      • Patients with other cutaneous diseases.

    • Patient's having dandruff (scaly scalp) even if not symptomatizing.

    • Pregnant and lactating females, children, prisoners, cognitively impaired or mentally disabled subjects.

    • Patients with autoimmune diseases.

    • Patients with immunodeficiency diseases.

    • Immunosuppressed patients e.g. HIV, diabetics, organ transplant, malignancy, patients taking immunosuppressive drugs e.g. chemotherapy, cortisone.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Kasr Al Ainy Hospital, Cairo university Cairo El Manial Egypt 11956

    Sponsors and Collaborators

    • Kasr El Aini Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Rana F Hilal, MD, Lecturer of dermatology, Kasr El Aini Hospital
    ClinicalTrials.gov Identifier:
    NCT04769804
    Other Study ID Numbers:
    • PolymorphismTV
    First Posted:
    Feb 25, 2021
    Last Update Posted:
    Apr 26, 2021
    Last Verified:
    Feb 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Tinea Versicolor
    Pityriasis

    Study Results

    No Results Posted as of Apr 26, 2021